BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search
 Company Profile

 

Pearl Therapeutics 

200 Saginaw Drive

Redwood City  California  94063  U.S.A.
Phone: 650-305-2600 Fax: 650-568-1804


SEARCH JOBS




Industry
Medical Device

Segment
Start Up





 Company News
AstraZeneca PLC (AZN) in Deal for Pearl Therapeutics Worth Up to $1.15 Billion 6/10/2013 7:21:23 AM
Pearl Therapeutics Presents Dose-Ranging, Efficacy and Safety Results of PT003 as well as Components, PT001 and PT005 at American Thoracic Society Meeting 5/17/2013 9:10:22 AM
Pearl Therapeutics Initiates PT003 Phase 3 Program for the Treatment of Individuals with Moderate-to-Severe COPD 5/14/2013 9:42:12 AM
Pearl Therapeutics Receives Award for Innovative Co-Suspension Technology 3/14/2013 11:05:16 AM
Pearl Therapeutics Strengthens its Organization by Hiring Dr. Michael Riebe, an Industry Veteran in Respiratory Product Development 1/17/2013 9:09:19 AM
Pearl Therapeutics to Present at J.P. Morgan Healthcare Conference 1/4/2013 9:47:41 AM
Pearl Therapeutics Successfully Completes Phase 2 Program; Identifies Optimal Dose of PT003 and Its Components for Phase 3 10/24/2012 10:27:10 AM
Pearl Therapeutics Completes Phase 2b Study of Glycopyrrolate, Defines Dose-Response Curve and Identifies Optimal Dose of PT001 9/13/2012 9:52:09 AM
Pearl Therapeutics Receives TiE50 Award from Global Entrepreneurship Network 5/21/2012 12:11:14 PM
Pearl Therapeutics Phase 2b Twice-Daily Dosing Data Suggest Morning and Evening Benefit of PT003 in Patients with COPD 5/14/2012 10:44:47 AM
1234